Fatty acids modulate the efficacy of lutein in cataract prevention: Assessment of oxidative and inflammatory parameters in rats

Biochem Biophys Res Commun. 2018 Jun 2;500(2):435-442. doi: 10.1016/j.bbrc.2018.04.098. Epub 2018 Apr 19.

Abstract

Background: Effects of lutein (L) and fatty acids [linoleic acid (LA), eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) and oleic acid (OA)] on oxidative stress and inflammation in cataract were assessed.

Methods: Cataract was induced in male Wistar rat pups (11 days old) by giving a single dose of sodium selenite (25 μM/kg body weight) by IP. Lutein (1.3 μmol/kg body weight) was given one day before and five days after selenite injection as a micelle with 7.5 mM LA, or 7.5 mM EPA + DHA or 7.5 mM OA. Serum and lens oxidative stress and inflammatory parameters having a bearing cataract were assessed.

Results: Serum and lens nitric oxide, MDA and protein carbonyls were significantly (p < 0.05) increased in cataract compared to control and experimental groups. Catalase, SOD, glutathione peroxidase and glutathione transferase activity and glutathione level in serum and lens of cataract group were significantly (p < 0.05) decreased. Serum eicosanoids (PGE2, LTB4, and LTC4) and cytokines (CRP, TNF-α, IL1-β, and MCP-1) were significantly (p < 0.05) increased in cataract. The activity of cPLA2 and Cox-2 in cataract lens was higher (p < 0.05) compared to other groups. EP-1, NOS-2 and NF-kB expression were higher (p < 0.05) in cataract. The ratio of water insoluble to water soluble protein was increased in cataract lens. Group administered with L + EPA + DHA exhibited highest cataract prevention compared to L + LA and L + OA. Pups given lutein with EPA + DHA had the highest amount of lutein in the lens.

Conclusions: The anti-cataract activity of lutein was influenced by fatty acids and found to be highest with EPA + DHA compared to LA or OA.

Keywords: Cataract; Fatty acids; Inflammation; Lutein; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Biomarkers / blood
  • Cataract / blood
  • Cataract / drug therapy*
  • Cataract / prevention & control*
  • Cyclooxygenase 2 / metabolism
  • Cytokines / blood
  • Eicosanoids / blood
  • Eye Proteins / metabolism
  • Fatty Acids / pharmacology
  • Fatty Acids / therapeutic use*
  • Glutathione / blood
  • Glutathione / metabolism
  • Inflammation / drug therapy*
  • Inflammation / pathology
  • Lens, Crystalline / metabolism
  • Lens, Crystalline / pathology
  • Lutein / pharmacology
  • Lutein / therapeutic use*
  • Male
  • Models, Biological
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress* / drug effects
  • Phospholipases A2, Cytosolic / metabolism
  • Rats
  • Receptors, Prostaglandin E, EP1 Subtype / metabolism
  • Solubility
  • Water

Substances

  • Antioxidants
  • Biomarkers
  • Cytokines
  • Eicosanoids
  • Eye Proteins
  • Fatty Acids
  • NF-kappa B
  • Receptors, Prostaglandin E, EP1 Subtype
  • Water
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Phospholipases A2, Cytosolic
  • Glutathione
  • Lutein